Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
UBS
US Army
McKinsey
Dow
US Department of Justice
AstraZeneca
Johnson and Johnson
Federal Trade Commission
Accenture

Generated: August 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 6,172,046 protect, and when does it expire?


Patent ► Subscribe protects REBETOL and is included in two NDAs.

Protection for REBETOL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: ► Subscribe

Title: Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
Abstract:There is disclosed a method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks.
Inventor(s): Albrecht; Janice K. (Winter Park, FL)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:08/938,033
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck Sharp Dohme
REBETOL
ribavirin
CAPSULE;ORAL020903-001Jun 3, 1998DISCNNoNo► Subscribe► SubscribeY
Merck Sharp Dohme
REBETOL
ribavirin
CAPSULE;ORAL020903-002Jul 25, 2001ABRXYesYes► Subscribe► SubscribeY
Schering
REBETOL
ribavirin
SOLUTION;ORAL021546-001Jul 29, 2003RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
QuintilesIMS
Baxter
Citi
US Department of Justice
Julphar
Colorcon
Harvard Business School
Johnson and Johnson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot